Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:8:871-879.
doi: 10.1016/j.toxrep.2021.04.003. Epub 2021 Apr 20.

Safety of COVID-19 vaccines administered in the EU: Should we be concerned?

Antonio F Hernández  1   2 , Daniela Calina  3 , Konstantinos Poulas  4 , Anca Oana Docea  5 , Aristidis M Tsatsakis  6
Affiliations

Safety of COVID-19 vaccines administered in the EU: Should we be concerned?

Antonio F Hernández et al. Toxicol Rep. 2021.

Erratum in

Abstract

The COVID-19 pandemic has had an unprecedented and devastating impact on public health, society and economics around the world. As a result, the development of vaccines to protect individuals from symptomatic COVID-19 infections has represented the only feasible health tool to combat the spread of the disease. However, at the same time the development and regulatory assessment of different vaccines has challenged pharmaceutical industries and regulatory agencies as this process has occurred in the shorter time ever though. So far, two mRNA and two adenovirus-vectored vaccines have received a conditional marketing authorisation in the EU and other countries. This review summarized and discusses the assessment reports of the European Medicine Agency (EMA) concerning the safety of the 3 vaccines currently used in the EU (Pfizer, Moderna and Astra-Zeneca). A particular focus has been paid to safety information from pre-clinical (animal) and clinical (phase 3 trials) studies. Overall, the most frequent adverse effects reported after the administration of these vaccines consisted of local reactions at the injection site (sore arm and erythema) followed by non-specific systemic effects (myalgia, chills, fatigue, headache, and fever), which occurred soon after vaccination and resolved shortly. Rare cases of vaccine-induced immune thrombotic thrombocytopenia have been reported for Vaxzevria. Data on long-term studies, interaction with other vaccines, use in pregnancy/breast-feeding, use in immunocompromised subjects, and in subjects with comorbidities, autoimmune or inflammatory disorders are still missing for these vaccines. Therefore, careful follow-up and surveillance studies for continued vaccine safety monitoring will be needed to ascertain the potential risks of such adverse events or diseases. In conclusion, the benefits and risks of current COVID-19 vaccines must be weighed against the real possibility of contract the disease and develop complications and long-term sequels; all this on the basis of the available scientific evidence and in the absence of unmotivated biases.

Keywords: Clinical trials; Covid-19; Public health; Safety; Side effects; Thrombosis; Vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors report no declarations of interest.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Diagram with the three vaccines against SARS-CoV-2 used currently used in vaccination campaigns in the EU.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Docea A.O., Tsatsakis A., Albulescu D., Cristea O., Zlatian O., Vinceti M., Moschos S.A., Tsoukalas D., Goumenou M., Drakoulis N., Dumanov J.M., Tutelyan V.A., Onischenko G.G., Aschner M., Spandidos D.A., Calina D. A new threat from an old enemy: re emergence of coronavirus (Review) Int. J. Mol. Med. 2020;45(6):1631–1643. doi: 10.3892/ijmm.2020.4555. - DOI - PMC - PubMed
    1. Farsalinos K., Poulas K., Kouretas D., Vantarakis A., Leotsinidis M., Kouvelas D., Docea A.O., Kostoff R., Gerotziafas G.T., Antoniou M.N., Polosa R., Barbouni A., Yiakoumaki V., Giannouchos T.V., Bagos P.G., Lazopoulos G., Izotov B.N., Tutelyan V.A., Aschner M., Hartung T., Wallace H.M., Carvalho F., Domingo J.L., Tsatsakis A. Improved strategies to counter the COVID-19 pandemic: lockdowns vs. primary and community healthcare. Toxicol. Rep. 2021;8:1–9. doi: 10.1016/j.toxrep.2020.12.001. - DOI - PMC - PubMed
    1. Calina D., Sarkar C., Arsene A.L., Salehi B., Docea A.O., Mondal M., Islam M.T., Zali A., Sharifi-Rad J. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol. Res. 2020;68(6):315–324. doi: 10.1007/s12026-020-09154-4. - DOI - PMC - PubMed
    1. Tsatsakis A., Petrakis D., Nikolouzakis T.K., Docea A.O., Calina D., Vinceti M., Goumenou M., Kostoff R.N., Mamoulakis C., Aschner M., Hernández A.F. COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence. Food Chem. Toxicol. 2020;141 doi: 10.1016/j.fct.2020.111418. - DOI - PMC - PubMed
    1. Calina D., Hartung T., Mardare I., Mitroi M., Poulas K., Tsatsakis A., Rogoveanu I., Docea A.O. COVID-19 pandemic and alcohol consumption: impacts and interconnections. Toxicol. Rep. 2021;8:529–535. doi: 10.1016/j.toxrep.2021.03.005. - DOI - PMC - PubMed

LinkOut - more resources